Preventive Screening & Blood Biomarkers • ICD-10-CM R23.8
Blister
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM R23.8 • 5 Linked .gov / PubMed Citations
•
Governance: Dr. Marcus Thorne, MD, FACC (NPI #1184629314)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Blister Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Preventive Screening & Blood Biomarkers practice, Blister (ICD-10 R23.8) is stratified through USPSTF age/sex-appropriate preventive in Blister (R23.8: screenings), pairing targeted symptom control with longitudinal CBC, CMP & in Blister (R23.8: eGFR Baseline) surveillance.
- 2 Real-world patient consensus: Mapped to Preventive Screening & Blood Biomarkers under ICD-10-CM R23.8 for Blister clinical workups.
- 3 Typical cash cost range: Primary evaluation for Blister incorporates USPSTF age/sex-appropriate preventive in Blister (R23.8: screenings) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Blister monitoring tracks ApoB, HbA1c & in Blister (R23.8: hs-CRP Triad) toward ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R23.8).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Blister
What Is Blister?
Within Preventive Screening & Blood Biomarkers practice, Blister (ICD-10 R23.8) is stratified through USPSTF age/sex-appropriate preventive in Blister (R23.8: screenings), pairing targeted symptom control with longitudinal CBC, CMP & in Blister (R23.8: eGFR Baseline) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Blister (R23.8) center on or micronutrient cofactor in Blister (R23.8: reserves years prior). targeted preventive & labs interventions aim to normalize ApoB, HbA1c & in Blister (R23.8: hs-CRP Triad).
Common Symptoms & Clinical Signs
- • Presentation of Blister (R23.8): subtle fatigue, recovery in Blister (R23.8: lag, or micronutrient)
- • Secondary Blister clinical sign: age- or family-history-guided in Blister (R23.8: cancer, vascular, bone,)
- • Symptom flares in Blister correlating with ApoB, HbA1c & in Blister (R23.8: hs-CRP Triad) deviation outside ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R23.8)
- • Functional preventive & labs impact requiring USPSTF age/sex-appropriate preventive in Blister (R23.8: screenings) evaluation (R23.8)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Blister Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | R23.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Preventive Screening & Blood Biomarkers | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: ApoB, HbA1c & in Blister (R23.8: hs-CRP Triad) | ApoB < 80 mg/dL; HbA1c < 5.5%; hs-CRP < 1.0 mg/L (R23.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CBC, CMP & in Blister (R23.8: eGFR Baseline) | Within optimal preventive reference intervals (R23.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D, in Blister (R23.8: Ferritin & B12) | 25(OH)D 40–65 ng/mL; Ferritin 50–150 ng/mL (R23.8) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Blister
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Cold Sore Fever Blister Treatment (Docosanol) Cold Sore Fever Blister Treatment • RxCUI 797534 | Over-the-Counter Clinical Monograph | 94% | $6.6445 | $ 486.90 /mo |
| Errin (Norethindrone) Errin • RxCUI 748961 | Progestin | 77% | $0.0849 | $ 14.61 /mo |
| Incassia (Norethindrone) Incassia • RxCUI 2052064 | Progestin | 93% | $0.0849 | $ 14.61 /mo |
| Twirla (Levonorgestrel/Ethinyl Estradiol) Twirla • RxCUI 2396253 | Progestin | 80% | $66.7058 | $ 640.00 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Blister)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Modulation of the clonal burden in patients with lower-risk myelodysplastic Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. Leukemia • 2026-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41526614 ↗ |
| New Insights on Combined therapy with dutasteride and tadalafil vs dutasteride or tadalafil: What a 667-Participant Study Found The FDC 0.5/5 mg demonstrated superior efficacy, and an acceptable safety profile compared with dutasteride and tadalafil monotherapies in patients with BPH. BJU international • 2026-04-15 • Phase III Randomized Trial | N = 667 | 87/100 | PMID 41667130 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Blister Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Blister community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Blister.